[(2-烯丙基苯氧基)甲基]环氧乙烷 | 4638-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: [(2-烯丙基苯氧基)甲基]环氧乙烷
• 中文别名: 2-((2-烯丙基苯氧基)甲基)噁丙环
• 英文名称: 1-(2-allylphenoxy)-2,3-epoxypropane
• 英文别名: 1,2-epoxy-3-(2-allylphenoxy)-propane；1-(2’-allylphenoxy)-2,3-epoxypropane；(+/-)-2-((2-allylphenoxy)methyl)oxirane；2-[(2-prop-2-enylphenoxy)methyl]oxirane；3-(2-allylphenoxy)-1,2-epoxypropane；2-((2-allylphenoxy)methyl)-oxirane；((o-Allylphenoxy)methyl)oxirane
• CAS: 4638-04-4
• 化学式: C₁₂H₁₄O₂
• mdl: MFCD00127764
• 分子量: 190.242
• InChiKey: XENMLDGAMXHYMH-UHFFFAOYSA-N

物化性质

• 沸点：
  100-103 °C(Press: 0.6 Torr)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2910900090

反应信息

• 作为反应物：
  描述：

  [(2-烯丙基苯氧基)甲基]环氧乙烷 在 高血压蛋白原酶 作用下， 以 乙醇 、 异丙醚 、 水 为溶剂， 反应 123.0h， 生成 (S)-3-hydroxy-4-(2-allylphenoxy)butanenitrile
  参考文献：
  名称：

  New chemoenzymatic pathway for β-adrenergic blocking agents

  摘要：

  The lipase mediated kinetic resolution of pharmaceutically important beta-hydroxy nitrites is described in high enantionteric excesses and good yields. Some of the chiral beta-hydroxy nitriles have been employed in the synthesis of P-adrenergic blocking agents such as propranolol, alprenolol and moprolol. This protocol has also been extended for the enantiopure preparation of 5-(4-tosyloxymethyl)-1,3-oxazolidine-2-one and 3-liydroxy-4-tosyloxybutaiieiiitrile, chiral intermediates of high synthetic value. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.02.015
• 作为产物：
  描述：

  2-烯丙基酚 在 哌啶 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 0.67h， 生成 [(2-烯丙基苯氧基)甲基]环氧乙烷
  参考文献：
  名称：

  Antihypertensive indole derivatives of phenoxypropanolamines with .beta.-adrenergic receptor antagonist and vasodilating activity

  摘要：

  A series of 25 aryloxypropanolamines containing the 3-indolyl-tert-butyl [i.e., 1,1-dimethyl-2-(1H-indol-3-yl)ethyl] or substituted 3-indolyl-tert-butyl moiety as the N substituent is reported. These compounds have been tested for antihypertensive activity in spontaneously hypertensive rats (SHR), beta-adrenergic receptor antagonist action in conscious normotensive rats, vasodilating activity in ganglion-blocked rats with blood pressure maintained by angiotensin II infusion, and for intrinsic sympathomimetic action (ISA) in reserpinized rats. Some of the compounds exhibit antihypertensive activity in combination with beta adrenergic receptor antagonist and vasodilating action. The structure--activity relationships in these tests are discussed.

  DOI：

  10.1021/jm00177a015

文献信息

• Asymmetric hydrolytic kinetic resolution with recyclable polymeric Co(<scp>iii</scp>)–salen complexes: a practical strategy in the preparation of (S)-metoprolol, (S)-toliprolol and (S)-alprenolol: computational rationale for enantioselectivity
  作者：Tamal Roy、Sunirmal Barik、Manish Kumar、Rukhsana I. Kureshy、Bishwajit Ganguly、Noor-ul H. Khan、Sayed H. R. Abdi、Hari C. Bajaj

  DOI：10.1039/c4cy00594e

  日期：——

  epoxide (up to 46% compared to 50% theoretical yield) along with high enantioselectivity (up to 99%) were obtained in most cases using catalyst 1. Further studies showed that catalyst 1 could retain its catalytic activity for six cycles under the present reaction conditions without any significant loss in activity or enantioselectivity. To show the practical applicability of the above synthesized catalyst

  合成了一系列基于许多非手性和手性连接基的手性聚合Co（III）-salen配合物，并在末端环氧化物的不对称水解动力学拆分中评估了它们的催化性能。明智地研究了该连接基的作用，发现在手性BINOL型聚合物Salen配合物1的情况下，未反应的环氧化物的催化剂反应性和对映选择性的增加，特别是在短和短的情况下。长链脂族环氧化物。在大多数情况下，使用催化剂1可获得良好的分离度，即未反应的环氧化物的收率高（高达50％的理论收率的46％），以及高对映选择性（高达99％）。进一步的研究表明，催化剂在当前的反应条件下，图1所示的催化剂可以保持其催化活性六个循环而没有任何活性或对映选择性的明显损失。为了显示上述合成催化剂的实际适用性，我们使用配合物1以中等收率和高对映选择性合成了一些有效的手性β-阻滞剂。DFT（M06-L / 6-31 + G ** // ONIOM（B3LYP / 6-31G *：STO-3
• Continuous and convergent access to vicinyl amino alcohols
  作者：Tomoya Nobuta、Guozhi Xiao、Diego Ghislieri、Kerry Gilmore、Peter H. Seeberger

  DOI：10.1039/c5cc06093a

  日期：——

  Five active pharmaceutical ingredients (APIs) containing the vicinyl amino alcohol moiety were synthesized using a convergent chemical assembly system. The continuous system is composed of four flow reaction modules: biphasic...

  使用会聚化学组装系统合成了五个含有药物基氨基醇部分的活性药物成分（API）。连续系统由四个流动反应模块组成：双相...
• Aryloxypropanolaminotetralins, a process for their preparation and
  申请人：Elf Sanofi

  公开号：US05254595A1

  公开（公告）日：1993-10-19

  Aryloxypropanolaminotetralins with beta-antagonist activity of the formula ##STR1## wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described. A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.

  具有β-阻断活性的芳氧基丙醇胺四氢萘，其通式为##STR1##，其中R为氢、羟基或甲氧基，Ar为可选择性取代的芳香或杂芳香基团，以光学活性或非活性形式及其酸加成盐被描述。它们的制备方法以及含有通式(i)化合物或其药学上可接受的酸加成盐的药物组合物也被描述。
• BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR
  申请人：WAKO PURE CHEMICAL INDUSTRIES, LTD.

  公开号：US20160340374A1

  公开（公告）日：2016-11-24

  An object of the present invention is to provide a compound which is capable of attaining a composition having high storage stability without reacting with a base-reactive compound, even in the case of storage for a long period of time in a mixed state with the base-reactive compound, such as an epoxy-based compound, as well as capable of generating a strong base (guanidines, biguanides, phosphazenes or phosphoniums) by irradiation of light (active energy rays) or heating; a base generator comprising the compound; and a base-reactive composition comprising the base generator and the base-reactive compound. The present invention relates to the compound represented by the general formula (A); the base generator comprising the compound; and the base-reactive composition comprising the base generator and the base-reactive compound. (wherein R 1 represents an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; an alkenyl group; a 2-furylethynyl group; a 2-thiophenylethynyl group; or a 2,6-dithianyl group; R 2 to R 4 each independently represent an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; the aryl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; a furanyl group; a thienyl group; or an N-alkyl-substituted pyrrolyl group; Z + represents an ammonium cation having a guanidinium group, a biguanidium group or a phosphazenium group, or a phosphonium cation.)

  本发明的目的是提供一种化合物，能够在与碱反应性化合物混合状态长时间存储的情况下，仍能获得具有高储存稳定性的组合物，而不与碱反应性化合物发生反应，同时还能通过光照（活性能量射线）或加热产生强碱（胍胺、双胍胺、磷氮烷或磷銨）；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。本发明涉及由通式（A）表示的化合物；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。（其中R1代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；烯基；2-呋喃基炔基；2-噻吩基炔基；或2,6-二硫基基；R2到R4各自独立地代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基；呋喃基；噻吩基；或N-烷基取代的吡咯基；Z+代表具有胍胺基团、双胍胺基团或磷氮烷基团的铵阳离子，或磷銨阳离子。）
• Studies on Agents with Vasodilator and .BETA.-Blocking Activities. II.
  作者：Toshimi SEKI、Takayuki TAKEZAKI、Rikio OHUCHI、Hiroshi OHUYABU、Yoshitaka TANIMOTO、Takashi YAMAGUCHI、Norinobu SAITOH、Tsutomu ISHIMORI、Kikuo YASUDA

  DOI：10.1248/cpb.43.247

  日期：——

  A series of phenoxypropanolamines having a hydrazinopyridazinyl moiety was synthesized. Their hypotensive and β-blocking activities were evaluated after intravenous administration of the compounds to anethetized rats.Some of them exhibited both activities. In particular, compound 20k is a candidate for clinical use due to its hypotensive activity, equal to that of hydralazine, and its β-blocking activity, 2.7-fold more potent than that of propranolol.

  一系列含有哒嗪基肼结构的苯氧丙醇胺类化合物被合成，并通过静脉注射给麻醉大鼠后评估了它们的降压和β阻断活性。其中一些化合物显示了这两种活性。特别是化合物20k，由于其降压活性与肼达嗪相当，且β阻断活性比普萘洛尔强2.7倍，因此被认为是临床应用的候选药物。